Evidence map›Paper›PMID 38617231›Full record

ArticlebioRxiv : the preprint server for biology2024

Broadly neutralizing antibodies against emerging delta-coronaviruses.

Megi Rexhepaj, Young-Jun Park, Lisa Perruzza, Daniel Asarnow, Mathew Mccallum, Katja Culap, Christian Saliba, Giada Leoni, Alessio Balmelli, Courtney N Yoshiyama and 10 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Megi RexhepajDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Young-Jun ParkDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Lisa PerruzzaHumabs Biomed SA, a Subsidiary of Vir. Biotechnology, 6500 Bellinzona, Switzerland.
Daniel AsarnowDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Mathew MccallumDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Katja CulapHumabs Biomed SA, a Subsidiary of Vir. Biotechnology, 6500 Bellinzona, Switzerland.
Christian SalibaHumabs Biomed SA, a Subsidiary of Vir. Biotechnology, 6500 Bellinzona, Switzerland.
Giada LeoniHumabs Biomed SA, a Subsidiary of Vir. Biotechnology, 6500 Bellinzona, Switzerland.
Alessio BalmelliHumabs Biomed SA, a Subsidiary of Vir. Biotechnology, 6500 Bellinzona, Switzerland.
Courtney N YoshiyamaDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Miles S DickinsonDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Joel QuispeDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Jack Taylor BrownDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
M Alejandra TortoriciDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Kaitlin R SprouseDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Ashley L TaylorDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Tyler N StarrDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Davide CortiHumabs Biomed SA, a Subsidiary of Vir. Biotechnology, 6500 Bellinzona, Switzerland.
Fabio BenigniHumabs Biomed SA, a Subsidiary of Vir. Biotechnology, 6500 Bellinzona, Switzerland.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
University of Washington · USVir Biotechnology (Switzerland) · CHHoward Hughes Medical Institute · USHallym University Medical Center · KRUniversity of Utah · US

Funding

Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7M
Structure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI BALI PULENDRAN · 2022 to 2026
$15.3M
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4M
NIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS P01 AI167966
6 · The paper itself

Abstract

Porcine deltacoronavirus (PDCoV) spillovers were recently detected in children with acute undifferentiated febrile illness, underscoring recurrent zoonoses of divergent coronaviruses. To date, no vaccines or specific therapeutics are approved for use in humans against PDCoV. To prepare for possible future PDCoV epidemics, we isolated human spike (S)-directed monoclonal antibodies from transgenic mice and found that two of them, designated PD33 and PD41, broadly neutralized a panel of PDCoV variants. Cryo-electron microscopy structures of PD33 and PD41 in complex with the PDCoV receptor-binding domain and S ectodomain trimer provide a blueprint of the epitopes recognized by these mAbs, rationalizing their broad inhibitory activity. We show that both mAbs inhibit PDCoV by competitively interfering with host APN binding to the PDCoV receptor-binding loops, explaining the mechanism of viral neutralization. PD33 and PD41 are candidates for clinical advancement, which could be stockpiled to prepare for possible future PDCoV outbreaks.

Identifiers

PMID38617231
PMCPMC11014491
OpenAlexW4393385922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.